| Online-Ressource |
Verfasst von: | Meindl-Beinker, Nadja M. [VerfasserIn]  |
| Betge, Johannes [VerfasserIn]  |
| Gutting, Tobias [VerfasserIn]  |
| Burgermeister, Elke [VerfasserIn]  |
| Belle, Sebastian [VerfasserIn]  |
| Zhan, Tianzuo [VerfasserIn]  |
| Schulte, Nadine [VerfasserIn]  |
| Ebert, Matthias [VerfasserIn]  |
| Härtel, Nicolai [VerfasserIn]  |
Titel: | A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA) |
Verf.angabe: | Nadja M. Meindl-Beinker, Johannes Betge, Tobias Gutting, Elke Burgermeister, Sebastian Belle, Tianzuo Zhan, Nadine Schulte, Martin Maenz, Matthias P. Ebert and Nicolai Haertel |
E-Jahr: | 2019 |
Jahr: | 14 March 2019 |
Fussnoten: | Gesehen am 10.04.2019 |
Titel Quelle: | Enthalten in: BMC cancer |
Ort Quelle: | London : BioMed Central, 2001 |
Jahr Quelle: | 2019 |
Band/Heft Quelle: | 19(2019) Artikel-Nummer 231, 8 Seiten |
ISSN Quelle: | 1471-2407 |
Abstract: | Advanced esophageal squamous cell cancer (ESCC) is frequently diagnosed in elderly patients. The impact of 2nd line chemotherapy is poorly defined. Recent data demonstrated effectiveness of checkpoint inhibitors in different squamous cell carcinomas. Therefore, we assess combined nivolumab/ipilimumab as 2nd line therapy in elderly ESCC patients. |
DOI: | doi:10.1186/s12885-019-5446-2 |
URL: | kostenfrei: Volltext: https://doi.org/10.1186/s12885-019-5446-2 |
| DOI: https://doi.org/10.1186/s12885-019-5446-2 |
Datenträger: | Online-Ressource |
Sprache: | eng |
K10plus-PPN: | 1663067767 |
Verknüpfungen: | → Zeitschrift |
|
|
| |
Lokale URL UB: | Zum Volltext |
¬A¬ multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA) / Meindl-Beinker, Nadja M. [VerfasserIn]; 14 March 2019 (Online-Ressource)